Catalyst OrthoScience Announces Settlement of Patent Litigation with Shoulder Innovations

Agreement enables continued focus on differentiated innovation, growing adoption, and surgeon partnership

CATALYST LOGO COLOR HORIZ GRAY TEXT
CATALYST LOGO COLOR HORIZ GRAY TEXT

NAPLES, Fla.–(BUSINESS WIRE)–Catalyst OrthoScience Inc. (“Catalyst”), a private medical device technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced that it has entered into a settlement agreement with Shoulder Innovations, Inc. (“Shoulder Innovations”) to resolve all pending patent litigation between the two companies.

The agreement resolves the dispute in its entirety. The terms of the settlement agreement are confidential.

“Intellectual property is an important foundation for continued innovation, and we respect its role in advancing our industry,” said Carl O’Connell, president and chief executive officer of Catalyst. “We’re pleased to have reached an agreement that resolves this matter and allows both companies to move beyond it. With this behind us, Catalyst remains well positioned to continue delivering differentiated solutions that help surgeons work more efficiently and serve patients better.”

About Catalyst OrthoScience Inc.

Catalyst OrthoScience, founded in 2014 by orthopedic surgeon Dr. Steven Goldberg and based in Naples, Fla., is redefining shoulder replacement surgery. With a focus on less invasive techniques, fewer complications, and a more natural-feeling shoulder, Catalyst is breaking away from traditional approaches. Our total shoulder systems are engineered for precision and efficiency – preserving bone and soft tissue while enabling delivery of consistent, reproducible results. With a growing portfolio of issued and pending patents, Catalyst technology is available across the U.S. Learn more at www.catalystortho.com and connect with us on LinkedIn and Instagram.

Contacts

Nicole Nelson

Media Relations

(239) 325-9976

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.